Publication date: Jul 29, 2024
The COVID-19 vaccination programme in South Africa was rolled out in February 2021 via five delivery channels- hospitals, primary healthcare (PHC), fixed, temporary, and mobile outreach channels. In this study, we estimated the financial and economic costs of the COVID-19 vaccination programme in the first year of roll out from February 2021 to January 2022 and one month prior, in one district of South Africa, the West Rand district. Financial and economic costs were estimated from a public payer’s perspective using top-down and ingredient-based costing approaches. Data were collected on costs incurred at the national level and from the West Rand district. Total cost and cost per COVID-19 vaccine dose were estimated for each of the five delivery channels implemented in the district. In addition, we estimated vaccine delivery costs which we defined as total cost exclusive of vaccine procurement costs. Total financial and economic costs were estimated at US$8. 5 million and US$12 million, respectively; with a corresponding cost per dose of US$15. 31 (financial) and US$21. 85 (economic). The two biggest total cost drivers were vaccine procurement which contributed 73% and 51% to total financial and economic costs respectively, and staff time which contributed 10% and 36% to total financial and economic costs, respectively. Total vaccine delivery costs were estimated at US$2. 1 million (financial) and US$5. 7 million (economic); and the corresponding cost per dose at US$3. 84 (financial) and US$10. 38 (economic). Vaccine delivery cost per dose (financial/economic) was estimated at US$2. 93/12. 84 and US$2. 45/5. 99 in hospitals and PHCs, respectively, and at US$7. 34/20. 29, US$3. 96/11. 89 and US$24. 81/28. 76 in fixed, temporary and mobile outreach sites, respectively. Staff time was the biggest economic cost driver for vaccine delivery in PHCs and hospitals while per diems and staff time were the biggest economic cost drivers for vaccine delivery in the three outreach delivery channels. This study offers insights for budgeting and planning of COVID-19 vaccine delivery in South Africa’s public healthcare system. It also provides input for cost-effectiveness analyses to guide future strategies for maximizing vaccination coverage in the country.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Biggesteconomic | Budgeting and planning |
| February | Costing analysis |
| Hospitals | COVID-19 vaccination programme |
| COVID-19 vaccines | |
| Immunisation economics |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | VO | vaccination |
| disease | VO | COVID-19 vaccine |
| disease | VO | dose |
| disease | VO | vaccine |
| drug | DRUGBANK | Etoperidone |
| disease | VO | time |
| disease | VO | effectiveness |
| disease | VO | vaccination coverage |
| disease | IDO | country |
| disease | VO | vaccine dose |
| disease | VO | population |
| disease | VO | Comirnaty |
| disease | VO | Equity |
| disease | VO | effective |
| disease | VO | vaccinated |
| disease | VO | efficient |
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | malaria |
| pathway | KEGG | Malaria |
| disease | VO | primary vaccination |
| disease | VO | company |
| drug | DRUGBANK | Serine |
| disease | IDO | facility |
| disease | VO | vaccine transportation |
| disease | VO | storage |
| drug | DRUGBANK | Medical air |
| disease | MESH | uncertainty |
| disease | VO | adverse event |
| disease | VO | immunization |
| disease | VO | vaccine storage |
| disease | VO | URE |
| disease | MESH | morbidity |
| disease | MESH | Emergency |
| disease | MESH | AIDS |
| disease | IDO | process |
| disease | VO | USA |
| disease | VO | report |
| disease | VO | Gap |